Movement Alert｜Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally

Market Focus

Oct 06

On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock to a 52-week high of $187.69, suggesting a technical pullback driven by profit-taking.

UBS recently raised its price target to $225 from $175 and maintained a Buy rating, citing AstraZeneca's Serena-4 trial failure as validation of the liquid biopsy technology route. Additional positive catalysts included the inclusion of the company's colorectal cancer screening test in Evicore coverage and FDA approval of a breast cancer companion diagnostic.

Guardant Health Inc. is a precision oncology company providing blood-based tests, data sets, and analytics for cancer screening, recurrence monitoring, and treatment selection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1197717535"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197717535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197717535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-06 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197717535","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally","media":"Market Focus","content":"<p><p>On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock to a 52-week high of $187.69, suggesting a technical pullback driven by profit-taking.</p><p>UBS recently raised its price target to $225 from $175 and maintained a Buy rating, citing AstraZeneca's Serena-4 trial failure as validation of the liquid biopsy technology route. Additional positive catalysts included the inclusion of the company's colorectal cancer screening test in Evicore coverage and FDA approval of a breast cancer companion diagnostic.</p><p>Guardant Health Inc. is a precision oncology company providing blood-based tests, data sets, and analytics for cancer screening, recurrence monitoring, and treatment selection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-06 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock to a 52-week high of $187.69, suggesting a technical pullback driven by profit-taking.</p><p>UBS recently raised its price target to $225 from $175 and maintained a Buy rating, citing AstraZeneca's Serena-4 trial failure as validation of the liquid biopsy technology route. Additional positive catalysts included the inclusion of the company's colorectal cancer screening test in Evicore coverage and FDA approval of a breast cancer companion diagnostic.</p><p>Guardant Health Inc. is a precision oncology company providing blood-based tests, data sets, and analytics for cancer screening, recurrence monitoring, and treatment selection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1197717535","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197717535","pubTimestamp":1791296035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"走势警报|Guardant Health Inc. 常规交易下跌 5.36%，多重催化剂反弹后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On October 6, Guardant Health Inc. fell 5.36% in regular trading, trading at $177.2 per share with turnover of $118 million. The decline followed a prior-session gain of 5.30% that pushed the stock to a 52-week high of $187.69, suggesting a technical pullback driven by profit-taking.UBS recently raised its price target to $225 from $175 and maintained a Buy rating, citing AstraZeneca's Serena-4 trial failure as validation of the liquid biopsy technology route. Additional positive catalysts included the inclusion of the company's colorectal cancer screening test in Evicore coverage and FDA approval of a breast cancer companion diagnostic.Guardant Health Inc. is a precision oncology company providing blood-based tests, data sets, and analytics for cancer screening, recurrence monitoring, and treatment selection.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}